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Introduction
Clinical practice guidelines (CPGs), which provide systemic reviews of accumulated scientif-
ic evidence, are used by clinicians to choose optimal treatment modalities. In Korea, the Clinical 
Research Center for Stroke (CRCS) published the first version of its CPGs for stroke in Octo-
ber 2009; it was based on articles that had been reported before June 2007.1 Since then, major 
trials of decompressive surgery for malignant middle cerebral artery (MCA) have been pub-
lished, and the CRCS and Korean Society of Cerebrovascular Surgeons (KSCVS) therefore de-
cided to revise the CPGs to reflect this new evidence. 
To select source papers for the revision, we searched Pubmed for English-language articles 
published between July 2007 and May 2014 that contained the word “stroke,” plus any one of 
the following terms or phrases: “malignant MCA infarction,” “hemicraniectomy,” and “decom-
pressive surgery.” We retrieved 122 articles with the key words “stroke” and “malignant MCA in-
farction,” 136 articles with “stroke” and “hemicraniectomy,” and 225 articles with “stroke” and 
“decompressive surgery.” 
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We then narrowed this pool of articles down by limiting the 
search to prospective, randomized clinical trials, pooled analyses, 
and meta-analyses and found five such articles that were published 
during this period. 
We reviewed a total of five randomized, clinical trials,2-6 one 
pooled analysis,7 and one meta-analysis,4 including three stud-
ies2,3,7 that were mentioned in the first edition. 
The revised versions of the CPGs for decompressive surgery 
from the European Stroke Organization (ESO) (May 2008),8 the 
Scottish Intercollegiate Guidelines Network (December 2008)9, 
the National Clinical Guidelines for Stroke of the Royal College 
of Physicians (July 2008)10, and the American Heart Association 
(AHA)/American Stroke Association (ASA) guidelines (pub-
lished, respectively, in 2013 and 2014)11,12  were also considered. 
After we reviewed these articles and described new evidence 
in guidelines, each piece of evidence and recommendation was 
given a strength based on a definition of evidence level and rec-
ommendation grade used in the KSCVS and the CRCS guide-
lines (Table 1).
Our purpose in updating the CPGs is to incorporate the new 
evidence and to help physicians, patients with malignant MCA 
infarction, and their caregivers make decision regarding decom-
pressive hemicraniectomy. The recommendations were peer re-
viewed by steering committee members of the CRCS. A con-
sensus meeting convening experts from the Korean Stroke So-
ciety and the KSCVS was also held on January13, 2014, to deter-
mine the level of evidence and grade of recommendation. 
Previous recommendations for 
decompressive surgery 
The first version of the CPGs recommended decompressive 
surgery for malignant MCA infarction to reduce mortality and 
improve neurological outcome. This recommendation was gen-
erated from reviews of the European Stroke Initiative clinical 
practice guidelines,13 the 2007 AHA/ASA guidelines for the ear-
ly management of stroke,14 and two clinical trials2,3 and meta-
analyses,7 all published before June 2007. However, the earlier 
recommendations did not specifically state the timing of surgery 
or the age of the patients. 
Previous recommendation of the Korean CPGs for 
Stroke, version 1
With decompressive surgery for the relief of malignant edema 
due to cerebral infarction, the patient’s life can be saved and neu-
rological improvement can be expected. Patient age and the lo-
cation of infarction (i.e., nondominant or dominant hemisphere) 
may be factors that determine whether surgery should be per-
formed. It is recommended that patients with severe edema un-
dergo surgery. It is necessary, however, for the clinicians to deter-
mine whether the patient might be left with severe disability for 
life (level of evidence IIa, grade of recommendation B). 
New evidence from clinical trials and 
meta-analyses 
Sequential-Design, Multicenter, Randomized, 
Controlled Trial of Early Decompressive Craniectomy 
in Malignant Middle Cerebral Artery Infarction 
(DECIMAL Trial)
DECIMAL2 was a multicenter randomized clinical trial con-
ducted in France, compared decompressive surgery and medical 
management in patients with malignant MCA infarction. De-
compressive surgery was performed within 36 hours of symptom 
onset. The inclusion criteria for malignant MCA infarction were 
(1) National Institutes of Health Stroke Scale (NIHSS) score of 
16 points or more, (2) 1 more points on the NIHSS mental dete-
rioration inventory, and (3) computed tomography (CT) find-
Table 1. Evidence levels and recommendation grades used by the Korean Society of Cerebrovascular Surgeons and the Clinical Research Center for Stroke
Level of evidence (LOE)        
Ia Meta-analysis of randomized controlled trials
Ib At least one randomized controlled trial
IIa At least one well-designed controlled study without randomization
IIb At least one other type of well-designed quasi-experimental study
III Well-designed nonexperimental descriptive studies (e.g., comparative studies, correlation studies and case studies)
IV Expert committee reports or opinions and/or clinical experiences of respected authorities
Grade of recommendation
A (LOE Ia, Ib) At least one randomized controlled trial as part of the body of literature of overall good quality and consistency addressing specific recommendation
B (LOE IIa, IIb, III) Availability of well-conducted clinical studies but no randomized clinical trials on the topic of recommendation
C (LOE IV) Expert committee reports or opinions and/or clinical experiences of respected authorities; indicates absence of directly 
   applicable clinical studies of good quality
GPP (good practice points) Recommended best practice based on the clinical experience of the guideline development group
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ings suggestive of cerebral infarction in more than 50% of the 
MCA regions or a volume of cerebral infarction exceeding 145 
cm3 on diffusion-weighted brain magnetic resonance imaging 
(DWI). 
Total infarction volume on DWI can be measured in a semiau-
tomatic manner in malignant MCA infarction. It is calculated by 
adding all areas of abnormal hyperintense signal on each section, 
then multiplying by the slice thickness plus the intersection gap.15
The primary endpoint was good outcome, defined as a modi-
fied Rankin Scale (mRS) score of 0 to 3 at 6 months. The trial 
was terminated early by the safety monitoring committee, after 
38 patients had been enrolled, because of slow enrollment and 
plans for a pooled analysis with similar trials. The proportion of 
patients with mRS scores of 0 to 3 at 6 months was higher in the 
decompressive surgery group than in the medical management 
group, but the difference was not statistically significant (25.0% 
vs. 5.6%; P = 0.18). However, mortality was significantly reduced 
with decompressive surgery compared with that with medical 
management (25% vs. 77.8%; P < 0.0001), and the difference in 
mortality was maintained at 1 year. In conclusion, DECIMAL 
demonstrated that decompressive surgery was effective in reduc-
ing mortality by more than 50% compared with medical manage-
ment in patients with malignant MCA infarction.  
Decompressive Surgery for the Treatment of 
Malignant Infarction of the Middle Cerebral Artery 
(DESTINY)
DESTINY,3 a prospective multicenter randomized trial con-
ducted in Germany, compared decompressive surgery performed 
within 36 hours of symptom onset and conservative therapy in 
patients with malignant MCA infarction ages 18 to 60 years. The 
trial was designed as a sequential trial to assess 30-day mortality 
as the first efficacy endpoint and to sequentially determine the 
sample size needed to demonstrate the effect of decompressive 
surgery with the 6-month mRS score of 0 to 3 as a primary end-
point. 
Inclusion criteria for malignant MCA infarction were (1) clini-
cal presentation of MCA infarction with an NIHSS scores greater 
than 18 for nondominant hemisphere or an NIHSS score greater 
than 20 for dominant hemisphere, (2) decrease in level of con-
sciousness as defined by a score of 1 or greater on item 1a of the 
NIHSS, and (3) CT-documented unilateral MCA infarction, in-
cluding more than two thirds of the territory and including at 
least part of the basal ganglia.
After 32 patients were enrolled, the comparison for the first 
efficacy endpoint of 30-day mortality met statistical significance 
for the superiority of decompressive surgery over conservative 
therapy (12% vs. 53%; P = 0.02). Rather than continuous enroll-
ment to determine the effect of surgery on functional disability, 
the steering committee decided to stop the trial and instead per-
form a pooled analysis with similar trials. The difference in mor-
tality remained significant at 6 and 12 months (18% vs. 53%; 
P = 0.03). The proportion of mRS score of 0 to 3 at 6 months, 
which was considered the primary endpoint for the planned tar-
get sample size, was higher in the surgery group than in the con-
servative treatment group, but the difference was not statistically 
significant (47% vs. 27%; P = 0.23). However, the mRS distribu-
tion analysis showed a favorable shift toward better functional 
outcomes with decompressive surgery (P = 0.04). In conclusion, 
DESTINY demonstrated that decompressive surgery reduced 
mortality and resulted in a favorable shift in the mRS disability 
distribution.
Early decompressive surgery in malignant infarction 
of the middle cerebral artery: a pooled analysis of 
three randomized controlled trials
This pooled analysis7 included patients enrolled in the early 
terminated DECIMAL2 and DESTINY3 trials and in the ongo-
ing Hemicraniectomy After Middle cerebral artery infarction 
with Life-threatening Edema Trial (HAMLET).4 
The inclusion criteria for this pooled analysis were (1) age be-
tween 18 and 60 years, (2) surgery within 48 hours of onset of 
stroke, (3) NIHSS score higher than15, (4) decreased level of 
consciousness as defined by a score of 1 or higher on item 1a of 
the NIHSS, and (5) infarction of more than 50% of the MCA 
territory on CT or infarction volume greater than 145 cm3 on 
DWI.  
The primary endpoint was the proportion of patients with mRS 
scores of 0 to 4 at 1 year. A total of 93 patients (38 from DECI-
MAL, 32 from DESTINY, and 23 from HAMLET) were includ-
ed in this pooled analysis. At 1 year, 75% of the surgery group and 
24% of the control group had mRS scores of 0 to 4 (pooled abso-
lute risk reduction [ARR], 51% [95% confidence interval {CI}, 
34-69]; Number Needed to Treat [NNT]= 2; P< 0.0001 for sig-
nificance and P= 0.74 for heterogeneity). In addition, decompres-
sive surgery was associated with higher proportion of mRS 0 to 3 
outcome (43% vs. 21%; pooled ARR, 23% [95% CI 5-41]; 
NNT= 4; P= 0.014 for significance and P= 0.89 for heterogene-
ity) and better survival (78% vs. 29%; pooled ARR, 50% [95% CI 
33-67]; NNT= 2; P< 0.0001 for significance and P= 0.34 for het-
erogeneity). In conclusion, this pooled analysis demonstrated that 
decompressive surgery within 48 hours of onset reduced mortality 
and increased survival, with a good functional outcome, in patients 
with malignant MCA infarction.
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Surgical decompression for space-occupying cerebral 
infarction (the Hemicraniectomy After Middle Cerebral 
Artery Infarction with Life-Threatening Edema Trial 
[HAMLET])
HAMLET,4 a prospective multi-center randomized trial con-
ducted in the Netherlands, compared decompressive surgery 
within 96 hours of onset (longer than the intervals used in DEC-
IMAL and DESTINY) and best medical treatment in patients 
ages 18 to 60 years with space-occupying hemispheric infarction. 
The inclusion criteria for space-occupying hemispheric infarc-
tion were (1) MCA territory infarction with NIHSS score high-
er than 15 for right-sided lesions or higher than 20 for left-sided 
lesions, (2) gradual decrease in consciousness to a score of less 
than 14 on the Glasgow Coma Scale for right-sided lesions or an 
eye and motor score of less than 10 for left-sided lesions, and (3) 
ischemic changes on CT on two thirds of the MCA territory and 
the formation of space-occupying edema.
The primary endpoint was an mRS score of 0 to 3 at 1 year. 
Sixty-four patients were enrolled, and the median time between 
onset and randomization was 41 hours for the surgery group and 
45 hours for the medical treatment group (39 patients were ran-
domized within 48 hours). Decompressive surgery, compared 
with best medical treatment, did not increase the proportion of 
mRS score of 0 to 3 (25% vs. 25%; P > 0.999) but significantly 
reduced mortality (22% vs. 59%; ARR 38% [95% CI 15-60]; 
P = 0.002). In subgroup analyses, patients randomized within 48 
hours benefited from decompressive surgery for reducing mRS 
5 to 6 outcome (48% vs. 78%; ARR 30% [95% CI 1-59]) and 
mortality (19% vs. 78%; ARR 59% [95% CI 33-84]), whereas in 
those randomized after 48 hours, decompressive surgery did not 
significantly reduce mRS 5-6 outcome and mortality. 
In an updated meta-analysis of 109 patients randomized with-
in 48 hours in DECIMAL, DESTINY, and HAMLET, decom-
pressive surgery reduced mortality at 1 year (ARR 49.9% [95% 
CI 33.9-65.9]; P for heterogeneity = 0.53) and extreme disabili-
ty or death, defined as an mRS score of 5 to 6 (ARR 41.9% [95% 
CI 25.2-58.6]; P for heterogeneity = 0.52), and the effect on re-
ducing mRS outcome of 4 to 6 was statistically marginal (ARR 
16.3% [95% CI -0.1-33.1]; P for heterogeneity = 0.40).
In conclusion, decompressive surgery performed within 48 
hours reduced mortality and extreme disability or death, but 
there was no benefit for surgery performed up to 96 hours after 
onset. However, clinical trials and meta-analyses of decompres-
sive surgery in patients aged 60 and younger with malignant 
MCA infarction did not provide clear evidence of the effect of 
surgery on the quality of life.
Decompressive Surgery for the Treatment of 
Malignant Infarction of the Middle Cerebral Artery II 
(DESTINY II)
In contrast to the previous trials, which excluded patients old-
er than 60 years, DESTINY5 examined the efficacy of decom-
pressive surgery performed within 48 hours in patients older 
than 60 years. The other inclusion criteria were almost identical 
to those of the DESTINY trial, in which patients aged 18 to 60 
years were enrolled. In accordance with the pooled analysis of 
DECIMAL, HAMLET, and DESTINY data, the primary end-
point was functional outcome on the mRS score, dichotomized 
into 0 to 4 vs. 5 or 6 at 6 months. 
After 112 patients had been enrolled, the data and safety mon-
itoring board recommended that further recruitment be stopped 
in light of the findings of interim analysis of the primary end-
point for the first 82 patients. 
The proportion of patients who survived without severe dis-
ability (mRS 0-4) was 38% in the hemicraniectomy group and 
18% in the control group (odds ratio [OR] 2.91; 95% CI 1.06-
7.49; P = 0.04). This difference was mainly driven by the lower 
mortality in the surgery group (33% vs. 70%). However, no pa-
tient in either group achieved an mRS score of 0 to 2. The re-
maining disability proportions in the surgery and control groups, 
respectively, were 7% vs. 3% for mRS 3 outcome, 32% vs. 15% 
for mRS 4 outcome, and 28% vs. 13% for mRS 5 outcome. For 
the endpoints of activity of daily living, quality of life, and de-
pression, the intention-to-treat analysis (including dead patients, 
for whom worst values were assigned), showed that all of the 
measures significantly favored surgery. However, in the analysis 
restricted to patients who survived, the differences in these mea-
sures were not significant between the two groups.
In conclusion, DESTINY II showed that decompressive sur-
gery in patients older than 60 years is a lifesaving procedure and 
increases the chance of survival without complete dependency.
Even though the DESTINY II study proved that treatment is 
effective in patients 60 years and older, surgery in patients 80 
years and older must be carefully considered, and further studies 
are needed.  
Hemicraniectomy and Durotomy on Deterioration 
From Infarction-Related Swelling Trial (HeADDFIRST)
HeADDFIRST6 was a randomized pilot study intended to 
evaluate the benefit of surgical decompression for brain swell-
ing due to large supratentorial cerebral hemispheric infarction.
The inclusion criteria for brain swelling from large supratento-
rial cerebral hemispheric infarction were (1) age 18 to 75 years, 
(2) NIHSS score of 18 or more and responsiveness to minor 
stimulation (NIHSS item 1a < 2), and (3) hypodensity involv-
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ing at least 50% of the MCA territory on CT performed less than 
5 hours after the onset of stroke or hypodensity involving the en-
tire MCA territory on CT less than 48 hours after stroke onset. 
Among patients who met criteria 1 through 3, those with deteri-
oration within 96 hours were classified as 1 or more (according 
to these criteria: [i] Horizontal anterior septum pellucidum shift 
from the midline of at least 7.5 mm with unchanged or worsened 
neurological findings; or [ii] at least 4 mm of horizontal pineal 
shift from the midline with depression of arousability to the level 
of effortful awakening with immediate subsequent sleepiness or 
worse [NIHSS item 1a ≥ 2]), and were randomized to contin-
ued medical treatment only or medical treatment plus surgery. 
Twenty-five patients within 96 hours of stroke onset were ran-
domized. Among these patients, the primary endpoint of mortal-
ity at 21 days was 21% in the surgical group and 40% in the stan-
dardized medical treatment group, but the reduction was not sta-
tistically significant because of the small sample size (ARR 19% 
[95% CI -13%-50%]). No data on functional outcome or timing 
of the surgical intervention were reported in this study. Fourteen 
patients who failed to meet the randomization criteria and who 
underwent standardized medical treatment were alive at 21 days.
The strict randomization criteria of the HeADDFIRST study 
could effectively distinguish low risk from high risk of death re-
sulting from large supratentorial cerebral hemispheric infarction. 
Lower mortality in the medical treatment-only group than in 
other published trials suggests a benefit to standardizing medi-
cal management. 
Table 2 summarizes the designs and results of the randomized 
controlled trials and their meta-analysis testing decompressive 
hemicraniectomy in patients with malignant MCA territory in-
farction.
Surgical method for decompressive surgery for 
malignant MCA infarction 
In addition to randomized trials, clinical studies have been con-
ducted to evaluate surgical methods in Korea and other coun-
tries. In general, decompressive surgery consists of large hemicra-
niectomy and duraplasty including the temporal lobe, frontal 
lobe, and parietal lobe areas. The minimal anterior-posterior di-
ameter of the bone flap should be 12 cm.16,17 Special care should 
be taken not to damage the brain and blood vessels. With an inci-
sion of the dura mater and duraplasty involving the use of autolo-
gous periosteum or artificial dura matter, clinicians should ensure 
that the brain can be further relaxed. Clinicians who consider 
that it is difficult to decompress the brain solely with hemicrani-
ectomy and duraplasty because of severe swelling may choose to 
resect the temporalis muscle.18 Although some retrospective 
studies have reported the decompressive effect of the temporal 
lobectomy,19,20 randomized prospective clinical trials regarding 
the benefit of additional lobectomy should be mandatory be-
cause of the lack of clinical evidence. Moreover, additional lobec-
tomies were not conducted in the aforementioned prospective 
controlled randomized multicenter trials showing evidence sup-
porting the use of decompressive surgery for malignant MCA 
infarction.2-7 
Bone fragments can be preserved in a deep freezer or the pa-
tient’s abdominal wall. To date the optimal temperature for 
bone flap storage has not been clarified, but a range of -18°C to 
-83°C has been described.21 Cranioplasty, once the cerebral 
edema has subsided, is recommended. Cranioplasty is recom-
mended in a diverse range of times, from 6 weeks to 6 months. 
There is no clinical study regarding the effect of the timing of 
reinsertion on clinical outcome. According to the available per-
Table 2. Summary of randomized controlled trials and meta-analyses of decompressive surgery in patients with malignant middle cerebral artery infarction
Eligibility criteria Time window (month)
No. of 
patients
Age 
(year) Primary outcome
Functional outcome (%) 12-Month mortality (%)
Surgical Medical Surgical Medical
DECIMAL2 NIHSS > 15 and NIHSS Item 1a > 0,
   > 1/2 MCA territory or DWI > 145 mL
36 38 18-55 mRS 0-3 vs. 4-6 at 6 months 25 6 25 78
DESTINY3 NIHSS > 18– or 20+ and NIHSS
   Item1a > 0, > 2/3 MCA territory
36 32 18-60 mRS 0-3 vs. 4-6 at 6 months 47 27 18 53
Pooled analysis7 48 93 18-60 mRS 0-4 vs. 5-6 at 12 months 75 24 22 71
HAMLET4 NIHSS > 15– or 20,+ GCS< 14– or 10,+ 
   > 2/3 MCA territory 
96 64 18-60 mRS 0-3 vs. 4-6 at 12 months 25 25 22 60
Meta-analysis4 48 109 18-60 mRS 0-4 vs. 5-6 at 12 months 75 33 21 71
DESTINY II5 NIHSS≥ 15– or 20,+
   > 2/3 MCA territory
48 112 ≥ 60 mRS 0-4 vs. 5-6 at 6 months 38 18 43 76
HeADDFIRST6 NIHSS > 17, NIHSS Item 1a< 2,
   > 1/2 MCA within 5 hours or complete 
   MCA within 48 hours
96 24 18-75 mRS 0-5 vs. 6 at 21 days 79 60
DECIMAL, the French DEcompresssive Craniectomy In MALignant middle cerebral artery infarcts; DESTINY, the German DEcompressive Surgery for the Treatment of malignant 
INfarction of the middle cerebral artery trial; HAMLET, the Dutch Hemicraniectomy after Middle cerebral Artery infarction with Life-threatening Edema Trial; HeADDFIRST, 
Hemicraniectomy And Durotomy upon Deterioration From Infarction Related Swelling Trial; NIHSS, National Institute for Health Stroke Scale; MCA, middle cerebral artery; 
DWI, diffusion-weighted image; mRS, modified Rankin scale; GCS, Glasgow coma scale; -/+, non-dominant /dominant hemisphere. 
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tinent literature, timing itself is not related to complications, but 
early reinsertion, before 3 months of storage has elapsed, is gen-
erally recommended because of the risk of infection.22-27 Head-
ache, seizures, and local neurological deficits are possible be-
cause of sinking skin flap syndrome after the cerebral edema 
subsides. It is therefore desirable not to delay cranioplasty too 
long.28,29 Biocompatible porous polyethylene implants or cus-
tomized cranioplasty with polymethyl-methacrylate implants 
made with the use of a three-dimensional printer may be useful 
in the reconstruction of various cranial defects.30
Current status of revisions in other 
guidelines 
In 2003, the European Union Stroke Initiative (EUSI) stated 
that decompressive surgery might be performed for life-saving 
purpose in patients with malignant MCA infarction.13 In the re-
vised version, dated May 2008, decompressive surgery is recom-
mended in patients 60 years and younger within 48 hours of on-
set.8 Compared with the level of evidence III published in 2003, 
the revised version published in 2008 was upgraded to the level 
of class I evidence and the level of recommendation of A on the 
basis of a pooled analysis of the HAMLET,7 DECIMAL2 and 
DESTINY3 trials conducted in 2007.
Decompressive surgery within 48 hours of onset is also rec-
ommended (grade of recommendation A) in the revised ver-
sion of the Scottish Intercollegiate Guidelines Network, pub-
lished in December 2008, for patients with malignant MCA in-
farction ages 60 years and younger.9 
In July 2008, the National Clinical Guidelines for Stroke, from 
the Royal College of Physicians, also recommended decompres-
sive surgery within 48 hours of onset for the following patients: 
(1) those 60 years or younger, (2) those with clinical deficits 
suggestive of infarction in the MCA territory, (3) those with NI-
HSS scores higher than 15 points, (4) those with decreases in 
level of consciousness to a score of 1 or higher on the NIHSS 
Item 1a, and (5) those with signs on CT of an infarct affecting 
more than 50% of the MCA territory with or without additional 
infarction in the territory of the anterior or posterior cerebral ar-
tery on the same side, or an infarction volume greater than 145 
cm3 on DWI.10
In addition, the updated guidelines of the AHA/ASA, pub-
lished in 2013 and 2014,11,12 recommend that decompressive 
craniectomy with dural expansion be strongly considered in pa-
tients younger than 60 years with malignant MCA infarction 
who deteriorate neurologically within 48 hours despite medical 
therapy (class I, level of evidence B). Although the optimal trig-
ger for decompressive craniectomy is unknown, it is reasonable 
to use a decrease in level of consciousness, attributable to brain 
swelling, as the selection criterion (class IIa, level of evidence 
A). The efficacy of decompressive craniectomy in patients older 
than 60 years and the optimal timing of surgery are uncertain 
(class IIb, level of evidence C).
Revised Recommendation of the Korean 
Clinical Practice Guidelines for Stroke  
On the basis of the results of five randomized clinical trials, 
one pooled analysis, and one metaanalysis, it can be concluded 
that decompressive surgery undertaken within 48 hours reduc-
es mortality in patients with malignant MCA infarction who are 
60 years or younger and in those who are older than 60 (Table 
3). In addition, decompressive surgery increases the probability 
of survival with moderate or severe disability (mRS 0-4) in pa-
tients ages 60 or younger and survival with severe disability in 
patients older than 60. Accordingly, we have updated the rec-
ommendations regarding the level of evidence and the grade of 
recommendation, age as a factor, and timing of surgery. In con-
trast to the previous recommendations, we provide specific cri-
teria for malignant MCA infarction to help physicians select 
surgery candidates:
1) Decompressive hemicraniectomy within 48 hours after 
stroke onset is recommended in patients with malignant MCA 
infarction who are 60 years or younger (level of evidence Ia, 
grade of recommendation A) or older than 60 years (level of ev-
idence Ib, grade of recommendation A) and meet all of the fol-
Table 3. The 2015 update of the Korean Clinical Practice Guideline for stroke recommendations for decompressive craniectomy in patients with malignant MCA in-
farction  
Revised Recommendation of the Korean Clinical Practice Guidelines for Stroke  
1. Decompressive hemicraniectomy within 48 hours of stroke onset is recommended in patients with malignant MCA infarction who are 60 years or younger (level of 
    evidence Ia, grade of recommendation A) or older than 60 years (level of evidence Ib, grade of recommendation A) and meet all of the following criteria: 
    (1) clinical symptoms and signs of infarction in the MCA territory, 
    (2) NIHSS score of 16 points or more, 
    (3) decrease in level of consciousness as defined by an NIHSS item 1a score of 1 point or more, and 
    (4) infarction affecting more than 50% of the total MCA territory on CT or an infarct volume greater than 145 cm3 on diffusion-weighted MRI.
2. The physician should inform the patient’s family or guardian(s) of the potential outcome of survival with severe disability and lack of evidence of the benefit of surgery on 
    the quality of life (grade of recommendation GPP).
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lowing criteria: (1) clinical symptoms and signs of infarction in 
the MCA territory, (2) NIHSS score of 16 points or more, (3) 
decrease in the level of consciousness (defined as an NIHSS 
item 1a score of at least 1 point), and (4) infarction of more than 
50% of the total MCA territory on CT or an infarct volume 
greater than 145 cm3 on DWI.
2) The physician should inform the patient’s family or 
guardian(s) of the potential outcome of survival with severe dis-
ability and the lack of evidence for the benefit of surgery on the 
quality of life (grade of recommendation GPP).
Despite the effect of decompressive hemicraniectomy on re-
ducing mortality and severe disability, there is no clear evidence 
that the surgery improves quality of life in survivors. Further in-
vestigation of this aspect is needed.
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